Home/Pipeline/MOTO-CAR Immunotherapy

MOTO-CAR Immunotherapy

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Thunder Biotech

About Thunder Biotech

Thunder Biotech is an early-stage biotech firm pioneering CAR-macrophage (MOTO-CAR) immunotherapy for solid tumors. Founded in 2020 and led by its scientific founder, Dr. Kim O'Neill, the company is in the pre-clinical development stage and is privately funded. It aims to disrupt traditional cancer treatment norms by leveraging engineered macrophages to induce long-term anti-tumor immunity, targeting a significant unmet need in oncology.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed